Teoxane to Present How MLT 3.1 Adresses Rapid Weight-Loss-Induced Facial Changes

Teoxane to Present How MLT 3.1 Addresses Rapid Weight-Loss-Induced Facial Changes – A Multi-Layer, Holistic Approach Protocol for Facial Support, Volume Restoration and Skin Quality – at AMWC 2026

A new clinical framework addressing the facial impact of rapid metabolic transformation induced by incretin-based therapies will be introduced through a scientific symposium and educational sessions, positioning MLT 3.1 as an integrated response to structure, volume and skin quality. Two scientific posters will be presented, and one of them, as well as a dedicated symposium, will introduce how Teoxane’s MLT 3.1 holistic technique addresses a full response to rapid weight loss.

Teoxane will present MLT 3.1 (Multi-Layering Technique 3.1), a comprehensive, anatomy-based approach developed to address the facial consequences of rapid weight loss in the emerging metabolic era. As incretin-based therapies accelerate global weight reduction, facial tissues undergo profound structural and dermal changes requiring a new aesthetic strategy grounded in anatomical precision and tissue physiology. MLT 3.1 reflects Teoxane’s technique-driven and education-led philosophy: moving from isolated corrections toward coordinated, multi-layer facial optimisation.

At AMWC 2026, Teoxane will demonstrate how this established multi-layer framework provides a clinically relevant response to a rapidly emerging global phenomenon: the facial anatomical and dermal changes associated with accelerated weight loss. Importantly, MLT 3.1 integrates skin quality as a fundamental component. Weight loss does not merely stretch the skin differently — it alters hydration balance, surface luminosity, texture, and elasticity.

By combining volume and structure restoration with skin quality enhancement, MLT 3.1 hydrates, densifies, and brightens the skin while refining texture and supporting elasticity over time4. This personalised, multi-layered, innovative approach allows a natural, and harmonious appearance. Beyond in-clinic treatment, the integration of Teoxane Aesthetic Skincare ensures ongoing maintenance, turning a single session into a continuous journey of facial support and rejuvenation.

Teoxane Scientific Programming and Expert Education at AMWC 2026 Teoxane’s scientific contribution will be further highlighted during the Teoxane Symposium, taking place on Thursday, March 25th, from 14:00 to 16:00 at Prince Pierre Auditorium.

• Lecture: Understanding Facial Changes. Patient Expectations and Aesthetic Trends, by Dr Sabrina Shah-Desai
• Anatomy Lecture by Dr Gisella Criollo Lamilla • Live injection: Gen Z Full Face Beautification held by Dr Nabila Azib
• Case Study: Millennial Full-Face Rejuvenation, Male vs Female by Dr Navid Alizadeh
• Live injection: Perimenopausal Full Face Restauration held by Dr Paula Rosso

Presented by Dr Lee Walker (UK).

Dr Mounia Heddad-Masson, PhD, Director Global Medical Education & Medical Affairs at Teoxane, comments:  

"My scientific background is rooted in metabolic research, where I worked on glucose regulation mechanisms, including glucagon and incretin biology, within a preclinical and translational framework. The current expansion of incretin-based weight-loss therapies represents more than a metabolic shift; it is generating downstream implications for aesthetic medicine. The rapid expansion of weight-loss therapies has created a new aesthetic phenotype – one characterised by volume shifts, skin quality changes, and altered facial dynamics. Neither patients nor practitioners were fully prepared for this acceleration. Our role is to define clear frameworks and practical guidance that support clinicians in managing facial changes associated with rapid weight loss, ensuring safety, predictability, and long-term patient satisfaction”

1. ^{Molinari P, Urso SU, Faso C, Iacovone I, Mosti G. Mastering Midface Rejuvenation: A Proposal for a New
   Three-Layer, Ultrasound-Guided Technique. J Cosmet Dermatol. 2026 Jan;25(1):e70664}
2. ^{Haykal D, Hersant B, Cartier H, Meningaud JP. The role of GLP-1 agonists in esthetic medicine: Exploring
   the impact of semaglutide on body contouring and skin health. J Cosmet Dermatol. 2025
   Feb;24(2):e16716.}
3. ^{Negulescu V, Trevidic P, Poupard K. Non-surgical correction of facial lipoatrophy in people living with HIV
   using a range of commercially available injectable cross-linked hyaluronic acid dermal fillers: A
   prospective, single-blind study. Poster presented at: Aesthetic & Anti-Aging Medicine World Congress
   (AMWC) 2026; 2026; Monaco, Monaco.}
4. ^{Alizadeh N, Baranska-Rybak W, Criollo G, Lorenc P, Walker L. Injector-led case series on HA injectables
   for facial volume restoration and skin quality improvement in medication-driven weight loss. Poster
   presented at: Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2026; 2026; Monaco, Monaco}